Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase.

Ling LL, Xian J, Ali S, Geng B, Fan J, Mills DM, Arvanites AC, Orgueira H, Ashwell MA, Carmel G, Xiang Y, Moir DT.

Antimicrob Agents Chemother. 2004 May;48(5):1541-7.

3.

Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).

Miller WH, Seefeld MA, Newlander KA, Uzinskas IN, Burgess WJ, Heerding DA, Yuan CC, Head MS, Payne DJ, Rittenhouse SF, Moore TD, Pearson SC, Berry V, DeWolf WE Jr, Keller PM, Polizzi BJ, Qiu X, Janson CA, Huffman WF.

J Med Chem. 2002 Jul 18;45(15):3246-56.

PMID:
12109908
4.

Inhibitors of bacterial enoyl acyl carrier protein reductase (FabI): 2,9-disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, Payne DJ, Rittenhouse SF, Moore TD, DeWolf WE Jr, Keller PM, Qiu X, Janson CA, Vaidya K, Fosberry AP, Smyth MG, Jaworski DD, Slater-Radosti C, Huffman WF.

Bioorg Med Chem Lett. 2001 Sep 3;11(17):2241-4.

PMID:
11527706
5.

Structural basis and mechanism of enoyl reductase inhibition by triclosan.

Stewart MJ, Parikh S, Xiao G, Tonge PJ, Kisker C.

J Mol Biol. 1999 Jul 23;290(4):859-65.

PMID:
10398587
6.

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Lu H, Tonge PJ.

Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e. Review.

PMID:
18193820
7.

Phenylimidazole derivatives as specific inhibitors of bacterial enoyl-acyl carrier protein reductase FabK.

Ozawa T, Kitagawa H, Yamamoto Y, Takahata S, Iida M, Osaki Y, Yamada K.

Bioorg Med Chem. 2007 Dec 1;15(23):7325-36. Epub 2007 Sep 4.

PMID:
17892940
8.

1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl acyl carrier protein reductase (FabI).

Heerding DA, Chan G, DeWolf WE, Fosberry AP, Janson CA, Jaworski DD, McManus E, Miller WH, Moore TD, Payne DJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Smith W, Takata DT, Vaidya KS, Yuan CC, Huffman WF.

Bioorg Med Chem Lett. 2001 Aug 20;11(16):2061-5.

PMID:
11514139
9.

Escherichia coli enoyl-acyl carrier protein reductase (FabI) supports efficient operation of a functional reversal of β-oxidation cycle.

Vick JE, Clomburg JM, Blankschien MD, Chou A, Kim S, Gonzalez R.

Appl Environ Microbiol. 2015 Feb;81(4):1406-16.

10.

Molecular genetic analysis of enoyl-acyl carrier protein reductase inhibition by diazaborine.

de Boer GJ, Pielage GJ, Nijkamp HJ, Slabas AR, Rafferty JB, Baldock C, Rice DW, Stuitje AR.

Mol Microbiol. 1999 Jan;31(2):443-50.

11.

Sunflower (Helianthus annuus) fatty acid synthase complex: enoyl-[acyl carrier protein]-reductase genes.

González-Thuillier I, Venegas-Calerón M, Garcés R, von Wettstein-Knowles P, Martínez-Force E.

Planta. 2015 Jan;241(1):43-56. doi: 10.1007/s00425-014-2162-7. Epub 2014 Sep 11.

PMID:
25204631
12.

Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.

Seefeld MA, Miller WH, Newlander KA, Burgess WJ, DeWolf WE Jr, Elkins PA, Head MS, Jakas DR, Janson CA, Keller PM, Manley PJ, Moore TD, Payne DJ, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Uzinskas IN, Wallis NG, Huffman WF.

J Med Chem. 2003 Apr 24;46(9):1627-35.

PMID:
12699381
13.

A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase.

Levy CW, Baldock C, Wallace AJ, Sedelnikova S, Viner RC, Clough JM, Stuitje AR, Slabas AR, Rice DW, Rafferty JB.

J Mol Biol. 2001 May 25;309(1):171-80.

PMID:
11491286
14.

A mechanism of drug action revealed by structural studies of enoyl reductase.

Baldock C, Rafferty JB, Sedelnikova SE, Baker PJ, Stuitje AR, Slabas AR, Hawkes TR, Rice DW.

Science. 1996 Dec 20;274(5295):2107-10.

PMID:
8953047
15.

Discovery of a novel and potent class of FabI-directed antibacterial agents.

Payne DJ, Miller WH, Berry V, Brosky J, Burgess WJ, Chen E, DeWolf Jr WE Jr, Fosberry AP, Greenwood R, Head MS, Heerding DA, Janson CA, Jaworski DD, Keller PM, Manley PJ, Moore TD, Newlander KA, Pearson S, Polizzi BJ, Qiu X, Rittenhouse SF, Slater-Radosti C, Salyers KL, Seefeld MA, Smyth MG, Takata DT, Uzinskas IN, Vaidya K, Wallis NG, Winram SB, Yuan CC, Huffman WF.

Antimicrob Agents Chemother. 2002 Oct;46(10):3118-24.

18.

Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.

Afanador GA, Muench SP, McPhillie M, Fomovska A, Schön A, Zhou Y, Cheng G, Stec J, Freundlich JS, Shieh HM, Anderson JW, Jacobus DP, Fidock DA, Kozikowski AP, Fishwick CW, Rice DW, Freire E, McLeod R, Prigge ST.

Biochemistry. 2013 Dec 23;52(51):9155-66. doi: 10.1021/bi400945y. Epub 2013 Dec 13.

19.

Kinetic, inhibition and structural studies on 3-oxoacyl-ACP reductase from Plasmodium falciparum, a key enzyme in fatty acid biosynthesis.

Wickramasinghe SR, Inglis KA, Urch JE, Müller S, van Aalten DM, Fairlamb AH.

Biochem J. 2006 Jan 15;393(Pt 2):447-57.

20.

Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides.

He X, Alian A, Ortiz de Montellano PR.

Bioorg Med Chem. 2007 Nov 1;15(21):6649-58. Epub 2007 Aug 15.

Supplemental Content

Support Center